<SEC-DOCUMENT>0000947871-20-000739.txt : 20200917
<SEC-HEADER>0000947871-20-000739.hdr.sgml : 20200917
<ACCEPTANCE-DATETIME>20200917214658
ACCESSION NUMBER:		0000947871-20-000739
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200915
FILED AS OF DATE:		20200917
DATE AS OF CHANGE:		20200917

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Chimovits Erez
		CENTRAL INDEX KEY:			0001706399

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		201182667

	MAIL ADDRESS:	
		STREET 1:		P.O. BOX 4023
		CITY:			HERZLIYA PITUACH
		STATE:			L3
		ZIP:			4614001

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2020-09-15</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001720580</issuerCik>
        <issuerName>Adicet Bio, Inc.</issuerName>
        <issuerTradingSymbol>ACET</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001706399</rptOwnerCik>
            <rptOwnerName>Chimovits Erez</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADICET BIO, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>500 BOYLSTON STREET, 13TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>No securities are beneficially owned</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. (&quot;OrbiMed Israel GP&quot;) and OrbiMed Advisors Israel II Limited (&quot;OrbiMed Israel II&quot;) on the Issuer's board of directors. The reportable securities are owned by OrbiMed Israel Partners Limited Partnership (&quot;OIP&quot;) and OrbiMed Israel Partners II, L.P. (&quot;OIP II&quot;). OrbiMed Israel BioFund GP Limited Partnership (&quot;OrbiMed BioFund&quot;) is the general partner of OIP and OrbiMed Israel GP is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held by OIP. OrbiMed Israel GP II, L.P. (&quot;OrbiMed Israel GP II&quot;) is the general partner of OIP II and OrbiMed Israel II is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held by OIP II.</footnote>
        <footnote id="F2">OrbiMed Israel GP and OrbiMed Israel II exercise the investment and voting power described in footnote 1 through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP and OIP II.</footnote>
        <footnote id="F3">Each of the Reporting Person, OrbiMed Israel GP, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Israel GP, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Erez Chimovits</signatureName>
        <signatureDate>2020-09-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
